Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Female Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT07315360
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

NCT06655311
View directory record Official record
Conditions
Healthy, Hypercholesterolemia
Interventions
Enlicitide Chloride, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

NCT06106334
View directory record Official record
Conditions
Obesity, Healthy Volunteers
Interventions
S309309, Itraconazole
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-06700841

NCT04260464
View directory record Official record
Conditions
Healthy Volunteer, Renal Impairment
Interventions
PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

NCT04172987
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, EE/NGM
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

NCT04134715
View directory record Official record
Conditions
Healthy
Interventions
PF-06826647, Oral Contraceptive (OC)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 4, 2026, 6:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants

NCT00900276
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
immunologic technique, laboratory biomarker analysis, mass spectrometry
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

NCT04277624
View directory record Official record
Conditions
Healthy Volunteers
Interventions
fezolinetant - test formulation, fezolinetant - reference formulation
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 4, 2026, 6:40 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

NCT05841277
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
LY3819469
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 4, 2026, 6:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

NCT07377539
View directory record Official record
Conditions
Healthy Participants
Interventions
JZP047, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib in Healthy Female Participants

NCT01746732
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ortho-Cyclen, Evacetrapib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 4, 2026, 6:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers Study in Infants With Prior Neonatal Brain Injury

NCT07413900
View directory record Official record
Conditions
HIE - Hypoxic - Ischemic Encephalopathy, Perinatal Anoxic-ischemic Brain Injury, Premature Birth, Healthy Participants
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
3 Months to 24 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
43
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 6:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

NCT05891262
View directory record Official record
Conditions
Healthy Female Volunteers
Interventions
BMS-986196, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 4, 2026, 6:40 AM EDT